Home/Pipeline/PetXmark™

PetXmark™

Subcutaneous tissue marking for radiotherapy in dogs and cats

CommercialActive

Key Facts

Indication
Subcutaneous tissue marking for radiotherapy in dogs and cats
Phase
Commercial
Status
Active
Company

About Nanovi

Nanovi is a Copenhagen-based medical device company focused on precision oncology through its proprietary liquid fiducial markers. Its lead product, BioXmark®, is a CE-marked liquid marker designed to enhance target visibility for high-precision radiation therapy in humans, while PetXmark™ serves the veterinary oncology market. The company was acquired by CQ Medical in October 2023, signaling a successful exit and integration into a larger commercial entity. Nanovi's technology platform, developed in collaboration with DTU, addresses a critical need for flexible and accurate soft tissue marking across cancer types.

View full company profile

Therapeutic Areas